Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of MCMV5322A/MCMV3068A to prevent CMV disease in high-risk kidney transplant recipients
2012-002245-37Phase 2Completed
- Sponsor
- Genentech
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MCMV5322A, MCMV3068A in cytomegalovirus disease (CMV), sponsored by Genentech. Started Aug 2012; status: completed.
02
Drugs
MCMV5322AMCMV3068A
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2012-002245-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002245-37.